Delivery Order SPE2DB20D2014-SPE2DB25FC15V
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $4,575.52 on August 27, 2025, for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pens in 0.5 mL quantities. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 28, 2025, to be performed at the company's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's existing contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 16, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens with a ceiling value of $21,468.56. This is a firm fixed price delivery order with an ultimate completion date of June 17, 2025, and represents a non-competitive set-aside. The order is being fulfilled from AmerisourceBergen's place of performance in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.48 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pre-filled pens. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and carries an ultimate completion date of July 28, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary headquarters and...
- The Defense Logistics Agency awarded a delivery order valued at $35,643.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 7.5 mg/0.5 mL pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive, firm fixed-price delivery order carries no set-aside designation and will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a single delivery order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $29,274.42 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 10 mg/0.5 mL pens on August 6, 2025, with completion targeted for August 7, 2025. This firm fixed-price delivery order, which carries no set-aside designation, will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a single transaction under AmerisourceBergen's existing contractual relationship with DLA for...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens at a firm fixed price ceiling value of $1,143.87. This non-set-aside delivery order is scheduled for completion by August 27, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a discrete transaction under the company's broader pharmaceutical supply relationship with the Defense...
- The Defense Logistics Agency awarded a $16,652.51 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 31, 2025, with performance to be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete purchase requisition under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pen injections valued at $11,887.80. This is a firm fixed price delivery order with an ultimate completion date of May 28, 2025, and was competitively awarded without set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a pharmaceutical distributor and critical federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,538.13 to AmerisourceBergen Drug Corp for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens on August 4, 2025. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of August 5, 2025, and represents a direct pharmaceutical procurement to support federal healthcare needs. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens valued at $8,763.90. This contract represents a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and will be fulfilled at the contractor's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive...
- SPE2DB20D2014Indefinite Delivery Contract
- SPE2DB20D2014-SPE2DB25FC15VDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $21,737.00 to AmerisourceBergen Drug Corp on June 9, 2025, for the supply of Zepbound (tirzepatide) 5 mg/0.5 mL pens. The contract operates on a firm fixed-price basis with an ultimate completion date of June 10, 2025, and is being fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical federal medical supply vendor, AmerisourceBergen supports the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems through comprehensive pharmaceutical and medical supply solutions. The company's extensive federal portfolio demonstrates its capability to deliver specialized medications across multiple therapeutic domains to support military healthcare programs globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.7k | 6/9/25 |